Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products to become a leading generic pharma company.
Newbury Pharmaceuticals has raised $1.8M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
Newbury Pharmaceuticals is headquartered in Lund, Sweden.
Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products to become a leading generic pharma company.
Newbury Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Newbury Pharmaceuticals — Funding & Investors." VCBacked, March 4, 2024, https://www.vcbacked.co/company/newbury-pharmaceuticals. Accessed August 17, 2026.
VCBacked. (2024). Newbury Pharmaceuticals — Funding & Investors. Retrieved August 17, 2026, from https://www.vcbacked.co/company/newbury-pharmaceuticals
{{cite web |title=Newbury Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/newbury-pharmaceuticals |website=VCBacked |access-date=August 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated